Atrial Yüksek Hız Epizot Yönetimi

Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528.

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of internal medicine. 2007;146(12):857-67.

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European heart journal. 2021;42(5):373-498.

Simu G, Rosu R, Cismaru G, et al. Atrial high-rate episodes: a comprehensive review. Cardiovasc J Afr. 2021;32(2):102-7 DOI: 10.5830/cvja-2020-052.

Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugida F, Nakamura M. Efficacy of Antiarrhythmic Drug Therapy in Preventing Recurrence of Atrial Fibrillation and Long-Term Cardiovascular Prognosis in Patients With Asymptomatic Paroxysmal Atrial Fibrillation Comparison to Patients With Symptomatic Atrial Fibrillation. International Heart Journal. 2010;51(2):98-104.

Gorenek B, Bax J, Boriani G, et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Ep Europace. 2017;19(9):1556-78.

Özge MERT G, Kepez A, Uğur MERT K, Görenek B. What to do with device‐detected atrial high‐rate episodes: Summary of the evidences. Pacing and Clinical Electrophysiology. 2022;45(2):250-61.

Kreimer F, Mügge A, Gotzmann M. How should I treat patients with subclinical atrial fibrillation and atrial high-rate episodes? Current evidence and clinical importance. Clinical Research in Cardiology. 2022;111(9):994-1009.

Ozcan EE, Gorenek B. Corundum of stroke risk in atrial high rate episodes. Journal of Cardiology. 2019;74(4):394.

Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003;107(12):1614-9.

Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. New England journal of medicine. 2012;366(2):120-9.

Bertaglia E, Blank B, Blomström-Lundqvist C, et al. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. EP Europace. 2019;21(10):1459-67.

Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circulation: Arrhythmia and Electrophysiology. 2009;2(5):474-80.

Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. Journal of cardiovascular electrophysiology. 2009;20(3):241-8.

Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. Journal of cardiovascular electrophysiology. 2002;13(6):542-7.

Reiffel JA, Verma A, Kowey PR, et al. Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. JAMA Cardiol. 2017;2(10):1120-7 DOI: 10.1001/jamacardio.2017.3180.

Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021;398(10310):1507-16 DOI: 10.1016/s0140-6736(21)01698-6.

Chen J-Y, Chen T-W, Lu W-D. Atrial high-rate episodes predict major adverse cardio/cerebrovascular events in patients with cardiac implantable electrical devices. Scientific reports. 2021;11(1):18992.

Nakano M, Kondo Y, Nakano M, et al. Impact of atrial high-rate episodes on the risk of future stroke. Journal of Cardiology. 2019;74(2):144-9.

Li Y-G, Miyazawa K, Pastori D, Szekely O, Shahid F, Lip GY. Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project. International Journal of Cardiology. 2019;292:126-30.

Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094-9.

Witt CT, Kronborg MB, Nohr EA, Mortensen PT, Gerdes C, Nielsen JC. Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm. 2015;12(12):2368-75.

Boriani G, Glotzer TV, Ziegler PD, et al. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. Heart Rhythm. 2018;15(3):376-83.

Marinheiro R, Parreira L, Amador P, et al. Clinical impact of oral anticoagulation in patients with atrial high-rate episodes. Journal of Stroke and Cerebrovascular Diseases. 2019;28(4):971-9.

Park YJ, Kim JS, Park K-M, On YK, Park S-J. Subclinical atrial fibrillation burden and adverse clinical outcomes in patients with permanent pacemakers. Stroke. 2021;52(4):1299-308.

Healey JS, Alings M, Ha A, et al. Subclinical Atrial Fibrillation in Older Patients. Circulation. 2017;136(14):1276-83 DOI: 10.1161/circulationaha.117.028845.

Nasir JM, Pomeroy W, Marler A, et al. Predicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study. Heart Rhythm. 2017;14(7):955-61 DOI: 10.1016/j.hrthm.2017.04.026.

Sagris D, Georgiopoulos G, Pateras K, et al. Atrial High‐Rate Episode Duration Thresholds and Thromboembolic Risk: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2021;10(22):e022487.

Kirchhof P, Blank BF, Calvert M, et al. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017;190:12-8 DOI: 10.1016/j.ahj.2017.04.015.

Lopes RD, Alings M, Connolly SJ, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137-45 DOI: 10.1016/j.ahj.2017.04.008.

Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528.

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of internal medicine. 2007;146(12):857-67.

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European heart journal. 2021;42(5):373-498.

Simu G, Rosu R, Cismaru G, et al. Atrial high-rate episodes: a comprehensive review. Cardiovasc J Afr. 2021;32(2):102-7 DOI: 10.5830/cvja-2020-052.

Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugida F, Nakamura M. Efficacy of Antiarrhythmic Drug Therapy in Preventing Recurrence of Atrial Fibrillation and Long-Term Cardiovascular Prognosis in Patients With Asymptomatic Paroxysmal Atrial Fibrillation Comparison to Patients With Symptomatic Atrial Fibrillation. International Heart Journal. 2010;51(2):98-104.

Gorenek B, Bax J, Boriani G, et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Ep Europace. 2017;19(9):1556-78.

Özge MERT G, Kepez A, Uğur MERT K, Görenek B. What to do with device‐detected atrial high‐rate episodes: Summary of the evidences. Pacing and Clinical Electrophysiology. 2022;45(2):250-61.

Kreimer F, Mügge A, Gotzmann M. How should I treat patients with subclinical atrial fibrillation and atrial high-rate episodes? Current evidence and clinical importance. Clinical Research in Cardiology. 2022;111(9):994-1009.

Ozcan EE, Gorenek B. Corundum of stroke risk in atrial high rate episodes. Journal of Cardiology. 2019;74(4):394.

Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003;107(12):1614-9.

Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. New England journal of medicine. 2012;366(2):120-9.

Bertaglia E, Blank B, Blomström-Lundqvist C, et al. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. EP Europace. 2019;21(10):1459-67.

Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circulation: Arrhythmia and Electrophysiology. 2009;2(5):474-80.

Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. Journal of cardiovascular electrophysiology. 2009;20(3):241-8.

Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. Journal of cardiovascular electrophysiology. 2002;13(6):542-7.

Reiffel JA, Verma A, Kowey PR, et al. Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. JAMA Cardiol. 2017;2(10):1120-7 DOI: 10.1001/jamacardio.2017.3180.

Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021;398(10310):1507-16 DOI: 10.1016/s0140-6736(21)01698-6.

Chen J-Y, Chen T-W, Lu W-D. Atrial high-rate episodes predict major adverse cardio/cerebrovascular events in patients with cardiac implantable electrical devices. Scientific reports. 2021;11(1):18992.

Nakano M, Kondo Y, Nakano M, et al. Impact of atrial high-rate episodes on the risk of future stroke. Journal of Cardiology. 2019;74(2):144-9.

Li Y-G, Miyazawa K, Pastori D, Szekely O, Shahid F, Lip GY. Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project. International Journal of Cardiology. 2019;292:126-30.

Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094-9.

Witt CT, Kronborg MB, Nohr EA, Mortensen PT, Gerdes C, Nielsen JC. Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm. 2015;12(12):2368-75.

Boriani G, Glotzer TV, Ziegler PD, et al. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. Heart Rhythm. 2018;15(3):376-83.

Marinheiro R, Parreira L, Amador P, et al. Clinical impact of oral anticoagulation in patients with atrial high-rate episodes. Journal of Stroke and Cerebrovascular Diseases. 2019;28(4):971-9.

Park YJ, Kim JS, Park K-M, On YK, Park S-J. Subclinical atrial fibrillation burden and adverse clinical outcomes in patients with permanent pacemakers. Stroke. 2021;52(4):1299-308.

Healey JS, Alings M, Ha A, et al. Subclinical Atrial Fibrillation in Older Patients. Circulation. 2017;136(14):1276-83 DOI: 10.1161/circulationaha.117.028845.

Nasir JM, Pomeroy W, Marler A, et al. Predicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study. Heart Rhythm. 2017;14(7):955-61 DOI: 10.1016/j.hrthm.2017.04.026.

Sagris D, Georgiopoulos G, Pateras K, et al. Atrial High‐Rate Episode Duration Thresholds and Thromboembolic Risk: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2021;10(22):e022487.

Kirchhof P, Blank BF, Calvert M, et al. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017;190:12-8 DOI: 10.1016/j.ahj.2017.04.015.

Lopes RD, Alings M, Connolly SJ, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137-45 DOI: 10.1016/j.ahj.2017.04.008.